| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 119.62% | Wedbush | → $15 | Reiterates | Outperform → Outperform |
| 06/21/2023 | 119.62% | Wedbush | $17 → $15 | Maintains | Outperform |
| 05/18/2023 | 148.9% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 148.9% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 05/10/2023 | 148.9% | Wedbush | → $17 | Reiterates | → Outperform |
| 01/31/2023 | 46.41% | Wedbush | → $10 | Initiates Coverage On | → Outperform |
| 01/04/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/13/2022 | 104.98% | SVB Leerink | → $14 | Initiates Coverage On | → Outperform |
What is the target price for ARS Pharmaceuticals (SPRY)?
The latest price target for ARS Pharmaceuticals (NASDAQ: SPRY) was reported by Wedbush on August 14, 2023. The analyst firm set a price target for $15.00 expecting SPRY to rise to within 12 months (a possible 119.62% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?
The latest analyst rating for ARS Pharmaceuticals (NASDAQ: SPRY) was provided by Wedbush, and ARS Pharmaceuticals reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a reiterated with a price target of $0.00 to $15.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $6.83, which is within the analyst's predicted range.